Category: articles

Paul R. Edick President & Chief Executive Officer; Board Director

As President and Chief Executive Officer of MedPointe Pharmaceuticals, Paul Edick has assembled over the last twenty-eight years an outstanding track record of success in leading pharmaceutical organizations.

Mr. Edick joined MedPointe in 2002 as President of its Wallace Pharmaceuticals division. Shortly thereafter, he was named MedPointe President. Between 1994 and 2002, in a series of positions at G. D. Searle and its acquirer, Pharmacia Corporation, he led Searle’s US managed care organization (1994-95), its US marketing organization (1995-96), and its Global Pain & Inflammation Business – including the development of the launch strategy for Celebrex� (1996-97). In 1998, he assumed his first international leadership role, as he was named Searle’s VP-Canada & Latin America. A year later, he became President of Asia Pacific, Canada & Latin America. In 2000, upon Pharmacia’s acquisition of Searle, Mr. Edick was named Group Vice President and President, Asia Pacific/Latin America at Pharmacia.

His early career was focused on building basic skills in consumer products and prescription pharmaceuticals sales and marketing. He began his career as a Sales Representative at Procter & Gamble (1977-1978) and then joined Ortho Pharmaceutical, a division of Johnson & Johnson (1978-1990), where he became a US Regional Sales Manager in 1988. His first general management role was with Caremark, the former homecare services division of Baxter Healthcare (1990-1991). He further broadened his pharmaceutical marketing experience, domestically and internationally, with a Vice President, Group Account Management role at pharmaceutical ad agency, Hamilton Carver & Lee (1991-1994).

Mr. Edick serves on the Board of Directors of Informed Medical Communications, a leading communications company that delivers integrated biotechnology and pharmaceutical marketing programs for targeted and active groups of patients and medical professionals. He is also a Trustee of the Healthcare Institute of New Jersey,

Mr. Edick is a native of upstate New York and a graduate of Hamilton College.

Annual Declaration of Compliance for Fiscal Year 2005

MedPointe Pharmaceuticals, MedPointe Healthcare Inc., declares to the best of its knowledge and based upon a good faith understanding of the statutory requirements, that it has established a Comprehensive Compliance Program that meets the requirements of the California Health and Safety Code, sections 119400-119402. As of December 31, 2005, MedPointe declares that it is, in all material respects, in compliance with its Compliance Program and the California Health and Safety Code, sections 119400-119402. As its compliance program is specific to the MedPointe business and, as the concept of compliance continues to evolve, MedPointe will review its program at least annually. Through this review, MedPointe will continue its efforts to address the issues raised by the California law and to enhance the effectiveness of the program as needed to maintain a program that is reasonably designed to prevent or to detect and address violations of law or company policy.

Christopher Maltese Senior Vice President Business Information and Analytics

Christopher Maltese, Senior Vice President, Business Information and Analytics, has over twenty years of experience in leading teams within the finance, business development, information systems and market research areas. Over fifteen of those years are in the specialty pharmaceutical arena.
Mr. Maltese began his career in auditing for Litton Industries, Inc., a leading defense contractor. From 1986-1989, he worked as an internal auditor, moving in 1988 to the Airtron division working in product costing and pricing for the electronic warfare group.

In 1989, Mr. Maltese joined Carter-Wallace Inc. in the Wallace Pharmaceutical Division where he held many positions within the organization. During his tenure at Wallace Pharmaceutical, he held several senior positions within the finance, market research and business development groups. In 2001, Mr. Maltese joined MedPointe as the Senior Director of Market Analysis when it acquired Carter-Wallace. Mr. Maltese was promoted to Vice President – Business Analytics in 2002 and in early 2005 to his current position.

He plays a key leadership role in the Company’s business information (IT), business development, analytics and market research activities.

• Information Technology group – SAP enterprise systems, information infrastructure, communication systems
• Sales Systems – sales force automation systems and sample monitoring and analysis
• Sales Analysis – sales force design, territory mapping incentive compensation plans and processing
• Market Research – productions and analysis of primary and secondary data in support of MedPointe’s marketed brands and potential business development deals

Chris received his BS in accounting from Rider University. He is a Certified Public Accountant licensed in NJ.

As Non-Executive Chairman of MedPointe, Tony Wild brings a wealth of experience gained in a global career of 30 years in the pharmaceutical industry. Until the merger of Warner-Lambert with Pfizer in June 2000, he served as Executive Vice President of Warner-Lambert and President of its Pharmaceutical Sector, with worldwide responsibility for Warner-Lambert’s pharmaceutical commercial operations and research and development. Under Tony’s leadership, Warner-Lambert’s pharmaceutical business grew from $2.1 billion in sales with 14,000 employees in 199

Anthony H. Wild, PhD Chairman and CEO Anthony H. Wild, Ph.D., is Chairman and CEO of MedPointe. He brings a wealth of experience gained in a global career of 30 years in the pharmaceutical industry.

Prior to joining MedPointe, Tony served as Executive Vice President of Warner-Lambert and President of its Pharmaceutical Sector (until the merger with Pfizer in June 2000), with worldwide responsibility for Warner-Lambert’s pharmaceutical commercial operations and research and development. Under his leadership, Warner-Lambert’s pharmaceutical business grew from $2.1 billion in sales with 14,000 employees in 1995 to an estimated $9.5 billion in 2000 with 21,000 employees and a $1.3 billion R&D budget. During this period, Tony oversaw a number of acquisitions including those of Jouveinal (France), Hickson (Eire) and Agouron (La Jolla), the setting up of the US joint-venture with Sankyo and that of the Pfizer global LIPITOR partnership.

Prior to joining Warner-Lambert in 1995 (initially as President of Parke-Davis North America before assuming global responsibilities in 1996), Tony spent 22 years with Schering-Plough Corporation in Switzerland, Sweden, South Africa, the Netherlands, United States, and culminating as President of Schering-Plough’s Japanese operations, a $500 million business, including a complex web of licensee/ licensor partnerships with major Japanese companies. Prior to that, he was employed at Sandoz AG in Basel, Switzerland, as a Development Chemist, where he worked on optimization and simulation of chemical processes.

Dr. Wild is a member of the Board of Advisors to the Joseph L. Mailman School of Public Health at Columbia University, a Trustee of the Healthcare Institute of New Jersey, past Chairman of the International Section of Pharmaceutical Research and Manufacturers of America, and past Governor of the American Chamber of Commerce in Japan.

Dr. Wild graduated from the University of York with a B.A. honors degree in Chemistry and received a Ph.D. in Physical Chemistry from the University of Cambridge (Churchill College), both in the U.K.

Mark S. Spiers Senior Vice President – Commercial Operations Mark S. Spiers, Senior Vice President – Commercial Operations, has acquired substantial experience and established a strong track record in running a range of commercial pharmaceutical organizations.

From 2001 until Pfizer’s acquisition of Pharmacia earlier this year, he served as Pharmacia’s Group Vice President and President of North American Operations, responsible for leading the company’s $7.5 billion US and Canadian pharmaceuticals business with direct oversight of sales, sales operations, managed care, distribution, training, IT, and e-channel business. During this period, Mr. Spiers’ organization launched Bextra�, currently one of the top-selling anti-arthritis medications in the US. In addition, he re-designed Pharmacia’s field force and managed care organizations and contributed to major changes in the company’s training and marketing practices. Immediately prior, Mr. Spiers was Pharmacia’s Group Vice President for Corporate Operations (2000-2001) and Group Vice President for US Operations (1999-2000) at Pharmacia & Upjohn, where he led a $3.5 billion US pharmaceuticals business.

Mr. Spiers began his pharmaceuticals career in 1975 at Bristol-Myers Squibb Company (BMS) as a Dallas, TX-based sales representative. He was promoted at BMS through a succession of progressively senior sales, marketing, and sales management positions from 1975-1999. Mr. Spiers was named Vice President of Sales at BMS in 1991, and in 1993, he went on to lead BMS’s Managed Care organization. In 1996, he moved to the BMS international organization and assumed responsibility for its Intercontinental marketing group for Anti-Infectives, Cardiovascular, CNS, and Oncology. In his last position with the company, he ran BMS’s tenth largest business unit as General Manager of Australia/New Zealand from 1997-1999.

Mr. Spiers is a former member of the Board of the National Pharmaceutical Council and the Australian Pharmaceutical Manufacturers Association.
He is a graduate of Austin College, Sherman, TX.